Cite

HARVARD Citation

    Wong, H. et al. (2020). Lorlatinib for the treatment of inflammatory myofibroblastic tumour with TPM4-ALK fusion following failure of entrectinib. Anti-cancer drugs. 31 (10), p. . [Online]. 
  
Back to record